Benefits
Stimulant-free fat loss and body composition improvement
InnoSlim® reduces intestinal glucose absorption (by downregulating SGLT1 glucose transporter) and activates AMPK-driven fat oxidation in adipocytes — producing fat loss without any stimulant, thyroid, or adrenal activation. Human studies confirm significant reductions in body weight, body fat percentage, and waist circumference with InnoSlim® supplementation.
Adiponectin elevation and insulin sensitivity
InnoSlim® significantly elevates adiponectin — the key insulin-sensitizing hormone secreted by healthy adipose tissue. Higher adiponectin improves muscle glucose uptake, reduces liver fat, and shifts whole-body metabolism toward fat oxidation rather than fat storage — a fundamental metabolic improvement relevant to obesity, metabolic syndrome, and type 2 diabetes prevention.
Blood glucose management
By reducing SGLT1-mediated glucose absorption in the intestine and improving peripheral insulin sensitivity through adiponectin elevation, InnoSlim® produces clinically relevant reductions in fasting blood glucose and postprandial glucose excursions — effects relevant for both weight management and metabolic health applications.
Mechanism of action
SGLT1 downregulation and AMPK activation
InnoSlim®'s specific ginsenoside profile (Rb1-dominant) downregulates SGLT1 (sodium-glucose cotransporter 1) in intestinal epithelium — reducing dietary glucose absorption into circulation. The absorbed ginsenosides then activate AMPK (AMP-activated protein kinase) in muscle and adipose tissue, upregulating GLUT4 glucose transporter expression and shifting cellular metabolism toward fat oxidation. Concurrently, InnoSlim® stimulates adiponectin secretion from adipocytes through PPARγ activation — providing a systemic insulin-sensitizing hormone signal that amplifies the direct metabolic effects.
Clinical trials
Human clinical study of InnoSlim® (250 mg/day, a Panax notoginseng + Astragalus membranaceus blend) effects on body weight, body fat, blood glucose, and adiponectin in overweight adults. Note: full peer-reviewed publication for InnoSlim®-specific clinical trials may be limited; primary documentation through NuLiv Science (manufacturer).
Two evidence streams. (1) PUBLISHED toxicology: 90-day rat study with 28-day recovery; methylliberine NOAEL determinations. (2) NON-PUBMED EFFICACY TRIAL: 16-week randomized double-blind crossover trial in 12 healthy adults (Huang 2022, J Biochemistry & Biotechnology — not PubMed-indexed); 5 capsules/day Astragalus + Notoginseng saponins. NCT03654391. Trial cited by NuLiv but full peer-reviewed PubMed publication is pending.
PUBLISHED (toxicology, PMID 31354884): InnoSlim® had no toxicologically relevant effects in 90-day rat study; safe up to highest doses tested. NON-PUBMED EFFICACY DATA (Huang 2022, J Biochem Biotechnol): manufacturer reports ~25% reduction in HOMA-IR (insulin resistance), 20% reduction in blood insulin, 5% reduction in total cholesterol, 8% reduction in LDL and blood glucose, ~30% reduction in triglycerides over 6 weeks. Mechanism: AMPK activation via adiponectin upregulation. Note: efficacy results have not been peer-reviewed in a PubMed-indexed journal; recommend tracking for forthcoming publication.